Lu AA24530 for the treatment of mood and anxiety disorders enters into clinical phase II

H. Lundbeck A/S and Takeda Pharmaceutical Company Limited today
announced the decision to investigate Lu AA24530 for the treatment of
depression in patients. Based on positive, pre-clinical results, as
well as the positive conclusion of the phase I trials in healthy
individuals, the first patient in a 600 patient phase II study has
been enrolled.

Lu AA24530, discovered by Lundbeck, belongs to a new chemical class
and represents an approach that is markedly different to any
currently marketed antidepressants. Lu AA24530 is being jointly
developed by Lundbeck and Takeda and is the second most advanced
compound in the collaboration on a new class of compounds to treat
mood and anxiety disorders."Lu AA24530 is an outcome of efforts to design and develop novel
psychotropics displaying clear-cut improvements in efficacy without
compromising patient tolerability and compliance," said Anders Gersel
Pedersen, head of Development at Lundbeck.

In September 2007, Lundbeck and Takeda formed an alliance to develop
and commercialize a portfolio of novel compounds in the US and Japan
for the treatment of mood and anxiety disorders, including Lu AA24530
and Lu AA21004, which is in a more advanced clinical development
stage."We are very pleased with the progression of development stage of Lu
AA24530, which is one of the compounds covered by our alliance with
Lundbeck," says Masaomi Miyamoto, General Manager of Pharmaceutical
Development Division of Takeda. "We will collaborate closely with
Lundbeck in the next clinical stage."

The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.




Takeda contact


Investors & Media:

Seizo Masuda
Coordinator, Corporate Communications Dept.
+81-3-3278-2037


Lundbeck contacts


Investors:                   Media:

Jacob Tolstrup               Caroline Broge
Director, Investor Relations Media Relations Manager
+45 36 43 30 79              +45 36 43 26 38



                      ________________________


Stock Exchange Release No 300 - 24 October 2007

About Takeda
Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global
company with its main focus on pharmaceuticals. As the largest
pharmaceutical company in Japan and one of the global leaders of the
industry, Takeda is committed to striving toward better health for
individuals and progress in medicine by developing superior
pharmaceutical products. Additional information about Takeda is
available through its corporate website, www.takeda.com.

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com.